News

A new study suggests that patients whose melanoma tumors have a high number of genetic mutations might respond best to drugs that block CTLA-4.

Melanoma is a genetically heterogeneous condition that will likely result in more diversified clinical management in the future.

Short ALA incubation coupled with blue light therapy yields effective, pain-free results.

Although relatively few physicians perform nonsurgical eye lifts, combining fillers and neuromodulators in this area can yield excellent results and high patient satisfaction, according to one international expert who presented at last year’s Cosmetic Bootcamp in Aspen, Colo.

Who would have thought that the cure for Methicilin-resistant Staphylococcus aureus (MRSA) may have been hiding in a book written in the 10th century?

Two of the most vexing skin conditions that dermatologists manage are melasma and vitiligo. In one condition, too much pigmentation is present because of genetic, hormonal and environmental factors. In the other, there is a lack of melanin in the skin, presumably on an autoimmune basis. In part two of this discussion on dyspigmentation conditions, Seemal Desai, M.D., who is a board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options for vitiligo with Dermatology Times editorial advisor, Dr. Norman Levine.

Indigo naturalis is an Old-World plant with multiple uses. Used in China for centuries as a traditional medicine, current clinical studies are proving its effectiveness as well as identifying mechanisms of action.

Electronic surface brachytherapy is a low-energy radiation treatment for skin cancer. Radiologists are required to administer the treatment, which is controversial in terms of reimbursement and collaborative requirements.

FDA has approved dinutuximab (Unituxin, United Therapeutics) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk pediatric neuroblastoma patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Insurance companies are paring down plans for patients, impacting patient ability to choose physicians. Dermatologists are being terminated from some plans based on practice profiling software that has insufficient risk analysis.

Potential errors related to EHRs include out-of-date medication lists, cut-and-paste incongruities and failure to heed electronically generated warnings, experts say.

Researchers have identified gene variants that could lead to new treatment targets and a better understanding of rosacea.

Maui – Taken together, two new studies suggest that among teens, indoor tanning is linked with other risky behaviors, and that tanners may be seeking a sort of natural high. This information may help dermatologists discuss healthy living in general with patients.

Key developments in battling sexually transmitted viruses include a new version of the HPV vaccine that protects against nine strains, and continued progress against HSV, says an expert.

A doctor performing a cosmetic filler injection is sued for battery by a patient. Consent was obtained, no untoward event happened and there were no long-term complications.

A new study, however, strongly refutes Silver sulfadiazine as being the gold standard for treating wounds. Learn why.

Researchers have identified the previously uncharacterized microtubule-severing enzyme, Fidgetin-like 2 (FL2), as a potential therapeutic target

A team of dermatologists tried to determine whether purse-string sutures improve cosmetic outcome, healing time, and scarring, when compared with second-intention healing for circular defects on the trunk and extremities. Get results from their findings

Growth factors are one of the most controversial cosmetic ingredients in terms of safety. Learn why.

Social media, an up-to-date web site, and a regular email newsletter highlighting what is new in your practice are ways to market yourself and your practice. Experts at the 2015 AAD also advise developing relationships with plastic surgery peers and carrying products for purchase at the office.

While non-physician clinicians cannot replace dermatologists, the role they play in dermatology practices is growing. However, there are key factors to consider, one expert says, including team structure, supervision and training.

Dermatologists should learn to recognize some rare and common skin conditions that may result from emerging medical therapies.

Dermatologists should refrain from developing an initial clinical impression and consider alternative diagnoses when seeing patients, an expert tells colleagues at the 73rd annual meeting of the American Academy of Dermatology.

While BDD is present in 2.4% of the general population, it can range from 9 - 14% in dermatology clinics. There are red flags that dermatologists can watch for, and depending on the severity, dermatologists may consider referring patients to mental health professionals.

Dermatologists should know the etiology of patient ulcers to most effectively manage them, according to an expert at AAD. He offered keys for treating wounds.

Two of the most vexing skin conditions dermatologists manage are melasma and vitiligo. Seemal Desai, M.D., board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options.

Outcomes for patients with Merkel Cell Carcinoma are typically poor and therapeutic options are limited, but advances in understanding the biology of the disease, as well as emerging cutting-edge treatments are expected to improve the outlook, experts say.

Does hair conditioner make an excellent shaving cream? to find out the answer keep reading.

Ipilimumab has been evaluated in the adjuvant setting. One expert predicts that ipilimumab’s positive effect on progression-free survival will translate into improvements in overall survival; however, he cautions that there is a risk:benefit ratio to be weighed.

An active ingredient used in the treatment of glaucoma is showing promise as a nonsurgical option in the reduction of periorbital fat.